Bendax

Quick links to important sections

Bendax

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bendax

Quick Facts

Property Description
Active ingredient Albendazole (C12H15N3O2S)
Form Oral tablet, Oral suspension
Pharmacological class Anthelmintic (Benzimidazole class)
General purpose Addressing parasitic worm infestations
Origin Synthetic compound

Defining Bendax: A Benzimidazole Anthelmintic

Bendax is a synthetic pharmaceutical product defined by its active ingredient, Albendazole, which is chemically classified as a benzimidazole carbamate. This places it firmly within the pharmacological class of anthelmintic drugs—medicines specifically developed to treat infections caused by parasitic worms, or helminths. Albendazole is utilized for its broad-spectrum action against a range of helminth infections and is a common compound in antiparasitic medicine.

Composition and Available Dosage Forms

The medication is a single-ingredient product designed for oral administration, utilizing Albendazole as the sole active compound. The drug's efficacy throughout the body relies on its systemic conversion into the active form, Albendazole sulfoxide. For patient use, Bendax is supplied in two main dosage forms: the solid oral tablet and the liquid oral suspension. The inclusion of the oral suspension form is crucial for accommodating the target audience that includes pediatric patients and individuals who may require the liquid form for easier swallowing.

General Purpose: Targeting Parasitic Worms

The overall purpose of this antiparasitic drug is to address human illnesses resulting from systemic parasitic worm infestations. The medicine works by selectively disrupting the parasite's ability to absorb essential nutrients, such as glucose, effectively depleting its energy stores. This systemic physiological action leads to the immobilization and death of the parasite, providing a comprehensive benefit in treating helminth-related conditions.

Regulatory References

  1. Albendazole: MedlinePlus Drug Information

What side effects are possible with Bendax?

Official Safety Profile of Bendax (Albendazole)

The safety profile of Bendax, which contains albendazole, is officially categorized by regulatory authorities based on the frequency and system-organ class of reported adverse reactions. This classification separates common, expected effects from rare, serious risks.

Frequency and Organ System Classification

Adverse reactions are grouped according to the physiological system affected and their reported incidence in regulatory documents:

  • Very Common: The most frequently documented effects include headache and mild to moderate elevations of hepatic enzymes (transaminases). This increase in liver enzymes is often reversible following the end of therapy.
  • Common: Other regular effects involve the gastrointestinal system (abdominal pain, nausea, vomiting) and the nervous system (dizziness). Reversible alopecia (hair thinning) is also classified as common and is primarily associated with long-term exposure.

Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes the potential for rare but serious adverse reactions, primarily affecting the blood and liver:

  • Serious Risks: These include rare instances of bone marrow suppression, potentially leading to conditions such as leukopenia, agranulocytosis, and aplastic anemia. Rare cases of hepatitis and acute liver failure are also documented.
  • Population Safety Notes: Due to potential risks, the medicine is generally contraindicated during pregnancy. Additionally, specific caution and mandatory monitoring are required for patients with pre-existing severe hepatic impairment.

Patients on this medication require routine monitoring of blood counts and liver function tests at defined intervals to observe for these officially documented changes. This structured safety approach reflects the regulatory commitment to communicating the medicine's full spectrum of risk.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Albendazole is defined by the potential for severe, documented complications affecting the hematologic and hepatic systems. Officially documented manifestations of high exposure or overdose may include signs of liver dysfunction, such as transaminase elevation, or manifestations of bone marrow suppression, such as a decrease in the white blood cell count (neutropenia). Other clinical signs noted in regulatory documents include headache, fever, and reversible alopecia.

The primary concern in an overdose scenario is the risk of severe, life-threatening blood dyscrasias. Regulatory information lists these severe outcomes as pancytopenia, aplastic anemia, agranulocytosis, and acute liver failure, noting reported fatalities associated with severe blood disorders. Patients with pre-existing liver disease are documented as being at an increased risk for bone marrow suppression and require specialized monitoring.

Due to the severity of these potential outcomes, the official prescribing information requires that an individual seek medical help immediately or contact a Poison Control Center if an overdose is suspected. Emergency services must be contacted immediately if the affected individual collapses, has a seizure, experiences difficulty breathing, or cannot be awakened. Management is officially restricted to symptomatic and general supportive measures, as no specific antidote is known. The regulatory documentation mandates monitoring of complete blood counts (CBC) and liver enzymes (transaminases) in these situations.

Therapeutic Uses of Bendax

Quick Facts

  • Targeted Conditions: Assists in the management of specific parasitic worm infections.
  • Primary Indications: Use is approved for neurocysticercosis and cystic hydatid disease.
  • Role in Therapy: Part of a medical regimen intended to address infections caused by certain tapeworm larvae.

Bendax (albendazole) is an oral medication utilized as part of a comprehensive therapeutic approach for certain parasitic infections. The medication's principal indications relate to two severe conditions caused by tapeworm larvae.

  • Neurocysticercosis: This condition involves active lesions caused by larval forms of the pork tapeworm (Taenia solium). Bendax is employed to manage this infection of the central nervous system.
  • Cystic Hydatid Disease: This involves larval forms of the dog tapeworm (Echinococcus granulosus) and may manifest as cysts in the liver, lung, and peritoneum. Bendax serves as a component of the medical management plan, often in conjunction with other interventions when appropriate, for this complex parasitic disease.

Consultation with a healthcare provider is necessary to determine if this medication is suitable for an individual's specific circumstances.

Regulatory References

  1. DailyMed NLM therapeutic overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Bendax

This map summarizes the official population eligibility and non-eligibility rules for Bendax (Albendazole), based exclusively on government-approved regulatory documents.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Patients generally established for its approved systemic indications.
Populations for whom use is not recommended Lactating (Breastfeeding) women for systemic use; Children under 6 years for systemic indications.
Populations for whom use is contraindicated Patients with known hypersensitivity to albendazole or other benzimidazole compounds.
Pregnant women or women thought to be pregnant.

Condition-Specific Eligibility Rules

Condition/Status Eligibility Restriction
Pre-existing Hepatic Disease Use requires special caution and close monitoring of liver enzymes and blood counts.
Females of Reproductive Potential Use requires a negative pregnancy test prior to initiation, and use of effective contraception during and after treatment.
Renal Impairment Pharmacokinetics in these patients have not been studied.

Connection to the overall eligibility profile

Regulatory documents establish clear limits, mandating absolute contraindication for pregnancy and hypersensitivity to the drug class. Eligibility is also restricted by age minimums, defining approved systemic use generally for those aged six years and older. Furthermore, the label requires the conditional eligibility of patients with pre-existing hepatic or hematologic conditions, necessitating pre-treatment testing and continuous monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Anticonvulsants (Enzyme Inducers), H2 Receptor Antagonists, Corticosteroids, Myelosuppressive Agents, Grapefruit-Containing Products
Specific interacting medicines (if explicitly listed) Cimetidine, Dexamethasone, Praziquantel, Phenytoin, Carbamazepine, Phenobarbital, Primidone, Ritonavir, Rifampicine

Official interaction statements:

  • Phenytoin, Carbamazepine, Phenobarbital, Primidone, Ritonavir, and Rifampicine are listed in regulatory sources as substances that may reduce the plasma concentrations of the active metabolite, albendazole sulfoxide, through enzyme induction.
  • Cimetidine, Dexamethasone, and Praziquantel co-administration is documented to increase the systemic exposure (C max and AUC) of albendazole sulfoxide.
  • Co-administration with other myelosuppressive agents is noted due to the documented additive risk of bone marrow suppression.
  • The medication must be administered with food (specifically a fatty meal) as this condition is officially documented to significantly enhance the absorption and bioavailability of the drug.
  • Grapefruit juice is documented to increase the systemic plasma levels of albendazole sulfoxide.

Connection to the overall interaction profile: The regulatory documents define the product’s interaction structure primarily through pharmacokinetic classification, identifying substances that either accelerate the clearance of the active metabolite via enzyme induction or inhibit its metabolism, resulting in increased exposure. This framework also includes a necessary drug-food interaction constraint, mandating co-administration with food to ensure bioavailability, and a caution concerning the additive pharmacodynamic risk of combining the medication with other myelosuppressive agents.

Mechanism of Action

Selective Inhibition of Parasitic beta-Tubulin

The pharmacological action of Bendax is executed by its active metabolite, Albendazole sulfoxide, which exerts a highly targeted effect on parasitic cellular function. The primary action is exerted within the domain of parasite cytoskeletal integrity. The active metabolite selectively binds to and inhibits the polymerization of beta-tubulin in the worm's cells, blocking the assembly of new microtubules. This molecular interference initiates the structural collapse of cellular components, particularly within the parasite's intestinal tissue.

Cascade of Energy Depletion and Metabolic Failure

This structural damage directly affects the domain of parasitic nutrient absorption. The loss of functional microtubules in the intestinal cells prevents the parasite from absorbing glucose from the host environment, causing a critical failure in its primary energy supply pathway. This metabolic disruption forces the helminth to deplete its internal glycogen stores, causing a significant ATP deficit that results in the functional immobilization of the parasite.

Dosage and Administration Information

The administration of Bendax (albendazole) is standardized for oral use, available as tablets and an oral suspension. A primary instruction governing its use is the requirement to take the medication with food, ideally a fatty meal, as this condition is necessary to significantly enhance the absorption of the active compound into the system.

Standard Dosing and Frequency

For the indications of Neurocysticercosis and Cystic Hydatid Disease, the drug is administered twice daily (BID), with the total daily amount divided into two equal doses. The specific dose is dependent on body weight:

  • Patients weighing 60 kg or more: Receive 400 mg per dose, twice daily.
  • Patients weighing less than 60 kg: Receive a total daily dose of 15 mg/kg body weight, divided into two doses, with a maximum total daily dose of 800 mg.

Administration and Course Duration

For patients, particularly young children, who have difficulty swallowing the tablet whole, the tablets can be crushed or chewed and then swallowed with a drink of water. The duration of therapy is strictly defined by the condition being addressed. Treatment for Neurocysticercosis generally lasts between 8 and 30 days. For Cystic Hydatid Disease, the medicine is administered in repeating courses: a 28-day treatment cycle is followed by a 14-day drug-free interval, repeated for a total of three cycles. For Neurocysticercosis, the administration procedure often involves the concurrent use of appropriate adjunctive therapies.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bendax (Albendazole)


Evidence for Use in Neurocysticercosis (NCC)

Randomized controlled trials (RCTs) have been conducted, exploring outcomes in patient groups receiving albendazole versus those receiving placebo or other antiparasitic agents for Neurocysticercosis (NCC). These trials examined outcomes related to physical discomfort and neurological function, such as measuring changes in the number and appearance of active brain lesions seen on imaging scans. Researchers also monitored the frequency of episodic or acute neurological changes, such as seizures, occurring in the study populations, which included both adult and pediatric patients.

Findings describe patterns observed in these short-term studies, with measurements focusing on changes in lesion appearance. Research indicates that changes measured during the study period varied, often depending on the type and location of the cysts. However, the evidence quality varies across studies, particularly when comparing different dosing schedules or when patients concurrently used other medications.


Evidence for Use in Cystic Hydatid Disease (CHD)

Albendazole was evaluated in studies for Cystic Hydatid Disease (CHD), which involves parasitic cysts, typically in the liver or lungs. The research explored short-term changes and long-term surveillance through RCTs and observational cohorts, where outcomes for albendazole were studied alongside those for surgical interventions or other cyst management techniques. Studies monitored outcomes related to systemic or functional imbalance by measuring changes in the size and viability of the cysts using imaging techniques.

Data show patterns related to cyst viability and changes in cyst size, with findings often depending on the patient's initial cyst stage and location. Because this is a complex condition, the evidence for albendazole is often derived from settings with varying symptom burdens.


What is Still Uncertain About Bendax Research

There is limited information for long-term outcomes, particularly concerning the durability of response. For NCC, data are still emerging and findings were mixed regarding long-term neurological symptom patterns over multiple years. For CHD, long-term effects are not fully established regarding the complete and permanent absence of cyst recurrence across all patient groups. Furthermore, the certainty remains low for certain aspects of treatment, such as the optimal duration and specific dosing schedule. Subgroup findings are uncertain, as comparative evidence is lacking regarding use in specific situations like cysts located outside the main brain parenchyma.

Key Studies & References

  1. Cysticidal drugs for neurocysticercosis: albendazole and praziquantel (Cochrane Review/Meta-analysis)
  2. Albendazole versus Praziquantel in the Treatment of Neurocysticercosis: A Meta-analysis of Comparative Trials
  3. Drug Treatment of Hydatid Cyst With Albendazole and Praziquantel in Humans (Quasi-experimental trial)

Frequently Asked Questions (FAQ)

Common questions about Bendax (FAQ)

Q: Can Bendax be taken by children?

Official product information indicates that the medication has been studied in pediatric patients for its approved uses. However, systemic use of the drug is generally defined as outside the population for whom use is recommended for children younger than six years old.


Q: Is it normal to feel a little tired when first starting Bendax?

The official list of common side effects does not specifically name fatigue or tiredness. However, regulatory documents do list dizziness as a common effect. Furthermore, a rare, serious risk of bone marrow suppression is documented, which can potentially lead to weakness.


Q: Does Bendax cause issues with liver function?

Regulatory documents indicate that mild to moderate, reversible elevations in liver enzymes are very common while using this medicine. Rare, but serious, risks include hepatitis and acute liver failure. Due to these potential effects, official labeling specifies the requirement for routine liver function tests for patients while taking this drug.


Q: Is Bendax available over the counter in some countries?

In countries with major regulatory agencies, such as the United States, the active ingredient in Bendax (Albendazole) is categorized as a prescription-only medicine. This requirement is in place due to the serious infections it treats and the potential for severe side effects that require medical monitoring.


Q: Can elderly patients use Bendax safely?

Official regulatory documents have not specifically detailed studies regarding the use of Bendax in the geriatric population (elderly patients). To date, no specific safety issues unique to this age group have been documented in the official labeling.


Q: How long does Bendax stay in your system after the last dose?

The time the drug's active form stays in the body is described by its half-life, which is the time it takes for half of the substance to be eliminated. Official information states that the active metabolite, albendazole sulfoxide, has an elimination half-life of approximately 8.5 hours.


Q: What are the signs that Bendax is working?

The medication works on a molecular level to cause the immobilization and death of the target parasite. When assessing the drug's effectiveness, a doctor primarily relies on monitoring tools. These include laboratory tests and imaging scans to track changes in lesion appearance or the viability of the parasitic cysts.


Q: Why is it important to complete the full course of Bendax?

The official label emphasizes that the medicine is intended to be taken until the entire prescribed amount is finished. Completing the full course is generally associated with achieving the intended therapeutic benefit and successful outcome against the parasitic infection.


Q: Is the effectiveness of Bendax affected by body weight?

Yes, according to official administration instructions, the correct dosage is determined based on the patient's body weight (categorized as 60 kilograms or more, or less than 60 kilograms). This individualized approach is defined in official guidance as the method used to achieve the proper systemic exposure for the medication.


Q: Why are there different dosing instructions for adults versus children for Bendax?

The official instructions for this drug categorize dosing based on the patient's body weight in kilograms, rather than strictly by age group. This weight-based measurement is used to calculate the systemic exposure that is defined as appropriate for the treatment of the infection in all patients.


Q: Why is Bendax sometimes called a 'broad-spectrum' drug?

The drug is often described as 'broad-spectrum' because its active ingredient, albendazole, has been studied and used to treat a wide range of different parasitic worm infections. This versatility extends beyond the two main conditions that have received formal regulatory approval in major regions.


Q: Does Bendax interact with common pain relievers?

Official regulatory sources list potential interactions with certain common over-the-counter pain relievers. These may include drugs containing active ingredients like acetaminophen (paracetamol) and acetylsalicylic acid (aspirin).


Q: What should I do if I forget to take a dose of Bendax?

Official regulatory guidance describes the protocol for a missed dose: the dose is generally taken as soon as it is remembered. If it is close to the next scheduled dose, the guidance describes skipping the missed dose and continuing the regular schedule. The guidance specifies that the dose should not be doubled.


Q: Can Bendax affect birth control pills?

Official labeling includes a caution that use is contingent on the patient utilizing effective contraception during and for a period after taking this medication. This requirement indicates the necessity for careful planning and consultation with a healthcare provider regarding specific contraceptive interactions.


Q: What is the role of Bendax in preventing recurrence of the condition it treats?

The primary role of the medicine is to kill the existing parasites, which is the defined purpose for eliminating the current infection. The duration of the treatment course is strictly defined to minimize the chances of the condition returning. Long-term studies regarding the complete and permanent absence of recurrence are still being evaluated.


Q: Is it common to have an allergic reaction to Bendax?

Regulatory documents list a history of hypersensitivity (allergic reaction) to the drug or other drugs in the same class (benzimidazoles) as an absolute contraindication for use. This means that the drug is not eligible for use in individuals who have had a prior allergic reaction.


Q: Does Bendax interact with herbal supplements?

Official regulatory interaction checkers list specific herbal products that may affect the medicine's systemic exposure. For example, some sources note a potential interaction with supplements such as Ginkgo Biloba.


Q: Is Bendax a new drug, or has it been around for a while?

The active ingredient in Bendax, Albendazole, has been in use for a long time. It was first marketed as an anthelmintic medication for human use in 1982.


Q: Do you need a prescription for Bendax in the US?

Yes, according to the U.S. Food and Drug Administration (FDA) and other major regulatory bodies, this is classified as a prescription medicine. This classification indicates that its use is subject to physician monitoring due to the serious conditions it treats and the potential for severe side effects.


Q: Are there any known interactions between Bendax and alcohol?

Official regulatory sources list a potential interaction between the medicine and alcohol. For this reason, official guidance indicates the necessity of avoiding alcohol consumption while taking the medication.


Q: Does Bendax interact with common blood thinners?

Yes, official drug interaction sources indicate potential interactions with certain types of blood thinners, such as those containing active ingredients like apixaban or acenocoumarol.


Q: Is Bendax used in veterinary medicine?

Yes, the active ingredient in this medication, albendazole, belongs to a class of drugs used in veterinary medicine. It is commonly utilized for controlling gastrointestinal parasites in certain animals, including livestock such like cattle and sheep.


Q: What happens if I miss several doses of Bendax?

The official labeling emphasizes the necessity of taking the medication regularly as prescribed and completing the entire course. Missing multiple doses is a significant deviation from the necessary regimen, and the required step is often defined as consultation with a healthcare provider.


Q: Does Bendax treat the symptoms or the cause of the condition?

The drug is designed to treat the root cause of the infection. It works by specifically targeting the parasitic worm, disrupting its structure, blocking its ability to absorb nutrients, with the intended purpose of causing the parasite's death.


Q: What is the difference in safety profile between Bendax and its generic version?

According to some regulatory-based dissolution studies, certain generic versions of the drug have demonstrated non-equivalence in how quickly they dissolve compared to the reference product. This difference in dissolution profiles can potentially affect the systemic exposure of the active medicine in the body.

How should Bendax be stored and disposed of?

How to Store and Dispose of BENDAX (Albendazole)

The official labeling provides strict requirements for the storage and disposal of this medicine, ensuring product integrity and environmental protection.

Storage Requirements

The product must be stored at room temperature and not above 30C (86F). It is mandatory to keep the medicine in its original container, tightly closed, and to protect it from light, moisture, and freezing. As a safety precaution, the drug must always be stored out of the sight and reach of children.

Stability and Disposal

For the oral suspension form, some labeling requires the product to be discarded 30 days after the initial opening. Disposal of unused or expired Bendax must be handled in accordance with local regulatory requirements. The medicine must not be thrown away with household trash or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bendax found in:

A-Z Index: